An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia

Leukemia. 2008 Dec;22(12):2269-72. doi: 10.1038/leu.2008.124. Epub 2008 May 29.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Middle Aged
  • Piperazines / therapeutic use*
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins p21(ras)
  • Pyrimidines / therapeutic use*
  • ras Proteins / genetics*

Substances

  • Antineoplastic Agents
  • Benzamides
  • KRAS protein, human
  • Piperazines
  • Proto-Oncogene Proteins
  • Pyrimidines
  • Imatinib Mesylate
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins